Literature DB >> 10208425

Suppression of src-induced transformed phenotype by expression of tropomyosin-1.

G L Prasad1, L Masuelli, M H Raj, N Harindranath.   

Abstract

Suppression of high M(r) tropomyosins (TMs) is a common feature of transformed cells. Previous work from this laboratory has demonstrated that the isoform 1 of TM, TM1, acts as an anti-oncogene in ras-transformed murine fibroblasts. In this study, we have investigated whether TM1 is a ras-specific suppressor, or a general suppressor protein of the cellular transformation. V-src transformed fibroblasts, which express decreased TM1, were transduced with a full-length cDNA to overexpress TM1. Both the control and the transduced cells expressed v-src kinase at comparable levels. TM1 expressing (src-T1) cells grew at a lower rate in monolayer, exhibited well spread, flat morphology than the control cells. Enhanced expression of TM1 resulted in improved microfilamental architecture. More significantly, src-T1 cells completely failed to grow under anchorage independent conditions. These data demonstrate that TM1 is as an anti-oncogene of functionally diverse oncogenes, and it is a class II tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208425     DOI: 10.1038/sj.onc.1202264

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts.

Authors:  Geraldine Pawlak; David M Helfman
Journal:  Mol Biol Cell       Date:  2002-01       Impact factor: 4.138

2.  Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.

Authors:  Janiel M Shields; Heena Mehta; Kevin Pruitt; Channing J Der
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells.

Authors:  Mario Gimona; Irina Kaverina; Guenter P Resch; Emmanuel Vignal; Gerald Burgstaller
Journal:  Mol Biol Cell       Date:  2003-03-20       Impact factor: 4.138

5.  Tropomyosin isoforms and reagents.

Authors:  Galina Schevzov; Shane P Whittaker; Thomas Fath; Jim Jc Lin; Peter W Gunning
Journal:  Bioarchitecture       Date:  2011-07-01

Review 6.  Interior decoration: tropomyosin in actin dynamics and cell migration.

Authors:  Justin G Lees; Cuc T T Bach; Geraldine M O'Neill
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

Review 7.  New insights into the regulation of the actin cytoskeleton by tropomyosin.

Authors:  C-L Albert Wang; Lynne M Coluccio
Journal:  Int Rev Cell Mol Biol       Date:  2010       Impact factor: 6.813

8.  Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts.

Authors:  Richard A J Janssen; Phillia N Kim; James W Mier; Deborah K Morrison
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

9.  From the Cover: Neutralization of terminal differentiation in gliomagenesis.

Authors:  Jian Hu; Allen L Ho; Liang Yuan; Baoli Hu; Sujun Hua; Soyoon Sarah Hwang; Jianhua Zhang; Tianyi Hu; Hongwu Zheng; Boyi Gan; Gongxiong Wu; Yaoqi Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

10.  Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma.

Authors:  M L Yager; J A I Hughes; F J Lovicu; P W Gunning; R P Weinberger; G M O'Neill
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.